

Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally

16 September 2025 | News

Molbio Diagnostics will leverage its global distribution network



Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.

Through this collaboration, Molbio will bring UE LifeSciences' iBreastExam® —a radiation-free, painless, and FDA-cleared screening device across India, Africa, the Middle East, CIS countries, the Philippines, Indonesia, and Vietnam.

Together, they aim to address the late detection of breast cancer, a leading cause of preventable breast cancer mortality. Molbio Diagnostics will leverage its global distribution network and expertise in expanding access to healthcare solutions to promote, market, sell, and distribute the iBreastExam® to public and private healthcare providers in these regions.

Ultra portable and easy to operate, iBreastExam brings early detection directly to women in their communities, overcoming barriers to mammogram access in low-resource settings. Secure cloud storage ensures seamless patient follow-up, helping save lives through timely diagnosis and care.